
18th Annual PERSPECTIVES IN UROLOGY POINT COUNTERPOINT 2009

Point-Counterpoint: Small Renal Masses

Best to Remove ~ *Paul D. Maroni, MD* Best to Watch ~ *Donald L. Lamm, MD*



Small renal mass Best to remove

■ Definition – enhancing renal mass ≤4cm (clinical T1a)

SRMs - Best to remove

Why?

- Minimal risk
- Effective treatment
- A real medical threat
- Improvements in peri-operative care

Risk of partial nephrectomy

metable at which adjusted metabolic provid homograps: which as high provide

æ

Laparoscopic versus Open Partial Nephrectomy: Analysis of the Current Literature


Prancesco Porpiglia', Alessandro Volpe, Michele Billia, Roberto Mario Soarpo

	# Pts	Size	Compl.	Medical	Leak	
Open	2756	3.2	21.3%	10%	3.9%	
Lap	1062	2.7	21.4%	9.6%	4.2%	
			Adapted from Porpiglia et al Eur Urol 2008			

Contemporary reality

- 1-3 day hospital stay (even with open surgery)
- 3-4 weeks of convalescence
- 98% 10-yr cancer specific survival
 - 100% with smaller tumors?
- ~4% local recurrence

Exceptionally low-risk in healthy patients with excellent cancer control



Cancer Risk

- Cripen et al Cancer 2009
- 173 patients with enhancing renal mass on AS
- 24 month median f/u
- 1.3% developed metastasis

• 15% exhibiting growth still had benign tumors **Development of metastasis in 2-yrs** as high as 10-yr CSS for PN. Growth a poor indicator of cancer.

Cancer Risk

Growth Kinetics of Renal Tumors/Crispen et al

low risk of disease progression, the excellent oncologic outcomes obtained with prompt surgical intervention continue to indicate that extirpative therapy in acceptable candidates should remain standard. Identification of clinical, radiographic, pathologic, and molecular correlates of a tumor's biologic potential is essential to avoid potential overtreatment of otherwise indolent asymptomatic tumors.

Real-life case

- 1987 63 yo male with abnormality on IVP in upper pole of right kidney
- 2004 81 yo male has 3-4cm mass identified in upper pole of right kidney. Cardiologist told him his cardiac risk was too high. Urologist told him his heart would kill him first.
- 2005 4cm continue to watch
- 2006 5cm continue to watch

~ Paul D. Maroni, MD

Real-life case

 2007 – 7cm, losing weight. Thinking more seriously about surgery. Saw cardiologist, PCP – all said not to operate.

UROLOGY 64: 909-913, 2004.

MANAGEMENT OF RENAL MASSES IN PATIENTS MEDICALLY UNSUITABLE FOR NEPHRECTOMY—NATURAL HISTORY, COMPLICATIONS, AND OUTCOME GATER V. A LABS, ISBN J. BEXARDLE HAL VARY, AN MIGHE ATELISM

• 36 patients with renal masses 3.5-20cm in size (median 6)

- 23 had biopsy confirming RCC
- No deaths from cancer progression
- Generally slow growth (0.4cm/year)

Real-life case

- 2007 7cm, losing weight. Thinking more seriously about surgery. Saw cardiologist, PCP – all said not to operate.
- 2008 10 cm, flank pain. Local spread to liver and lung.
- August 2008 dead from kidney cancer.

Acceptable candidates?

- How old is too old?
- How ill is too ill?

Example: elective abdominal aortic aneurysm repair in people over 80 years old

- Mortality 5.6% at one year
- Example: Hypertrophic cardiomyopathy
- In hospital death 6.7%

Ballotta et al Minerva Med 2009; Hreybe et al Clin Cardio 2006

Advice to patients (and practitioners)

- Do not discount surgery with the "eye-ball" test.
- Consultation with cardiologist and anesthesiologist.
- Balance surgical risks and cancer risks.
- Growth not indicative of cancer, but probably of malignant potential.